Discover more near‑term opportunities with better event intelligence.
Fundz combines its own real-time funding and M&A intelligence with executive moves, hiring shifts and other company changes, weighs each signal against your ideal customer profile, and delivers a ranked daily shortlist with the context and decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
ai3Bio raises $48M in Series A funding to advance platforms targeting Th17 cells. The funding will help reset the immune system at its root.
PRIVATESep 29, 2026
Amount Raised
$48 Million
Round Type
Series A
WatertownBiotechnologyHealth Care
Description
ai3Bio has launched with $48 million in Series A funding. This capital will be used to advance their platforms targeting Th17 cells in vivo. The company aims to reset the immune system at its root. The funding marks a significant step for ai3Bio.
Company Information
Company
ai3Bio
Location
Watertown, Massachusetts, United States
About
ai3Bio is a biotechnology company focused on resetting the immune system. The company aims to advance therapeutic platforms targeting Th17 cells in vivo. They have recently launched with significant Series A funding to support their innovative solutions.
Fundz sees it the moment ai3Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
WatertownBiotechnologyHealth Care